Literature DB >> 2788582

The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution.

R Seitz1, M Wolf, R Egbring, K Havemann.   

Abstract

In 42 patients with septic shock, 29 of whom underwent substitution with antithrombin III concentrate and fresh frozen plasma for coagulation disorders, the proteinase-inhibitor complexes thrombin-antithrombin III and neutrophil elastase-alpha 1 proteinase inhibitor, were elevated on admission. On admission, the elastase complex was significantly higher in the patients receiving substitution (p = 0.0039), but at the endpoint it was higher in the non-survivors (p = 0.0040). The elastase decrease was confined to the substitution group with the thrombin complex decreasing in both groups. Initially the thrombin complex correlated with prothrombin times and factor XIII, while the elastase complex correlated with creatinine, thrombocyte count and prothrombin times in the late stages. Hemostatic disturbance, thrombin generation and neutrophil elastase release were favorably influenced by substitution. Furthermore, in this uncontrolled pilot study, the survival rate was higher in the treated (16 of 29) than in the untreated (1 of 13) patients, although the treated patients initially had pronounced hemostatic disturbances.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788582     DOI: 10.1111/j.1600-0609.1989.tb01246.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  19 in total

Review 1.  [Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach].

Authors:  B Leithäuser; F R Matthias
Journal:  Med Klin (Munich)       Date:  1997-07-15

2.  Stabilized infective endocarditis and altered heparin responsiveness during cardiopulmonary bypass.

Authors:  Sungwon Na; Jae Kwang Shim; Duk-Hee Chun; Dae Hee Kim; Seong Wook Hong; Young-Lan Kwak
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

3.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

4.  Use of antithrombin III in critical patients.

Authors:  J M Díaz-Cremades; R Lorenzo; M Sánchez; M J Moreno; M J Alsar; J M Bosch; L Fajardo; D González; D Guerrero
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

Review 5.  Perspectives for the future.

Authors:  E F Mammen
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 6.  AT III in septicemia with DIC.

Authors:  H P Schuster
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

7.  Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass.

Authors:  H Lanquetot; T Leprince; S Ragot; C Boinot; C Jayle; R Robert; L Macchi
Journal:  Intensive Care Med       Date:  2008-06-25       Impact factor: 17.440

Review 8.  Current drug treatment strategies for disseminated intravascular coagulation.

Authors:  E de Jonge; M Levi; C P Stoutenbeek; S J van Deventer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

9.  Enhanced thrombin generation in patients receiving intensive care.

Authors:  G Balakrishnan; J Brownlie; R Webber; B Gibson
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

10.  Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.

Authors:  Massimo Franchini; Giuseppe Lippi; Franco Manzato
Journal:  Thromb J       Date:  2006-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.